Cardiopulmonary Treatments
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
92
NCT04919863
Safety, Tolerability and Pharmacokinetics of NTP42:KVA4
Phase: Phase 1
Role: Lead Sponsor
Start: May 24, 2021
Completion: Jan 20, 2022
NCT06092788
Safety, Pharmacokinetics (PK) and Relative Bioavailability of NTP42:KVA4 as a Solid Oral Dose
Start: Nov 24, 2023
Completion: Jan 17, 2024
Loading map...